The advent of monoclonal antibodies in the early 1980s further stimulated interest in this field and Drs Ziegler and Braude and their colleagues were among the first to capitalize upon this technology to create monoclonal antibodies against common LPS antigens, and more specifically lipid A and core polysaccharide determinants. Considerable efforts by these investigators and others were directed towards establishing the therapeutic efficacy of one such monoclonal antibody in both experimental animal models of LPS toxicity and experimental infection, and ultimately in a comprehensive placebo-controlled, double-blinded clinical study of patients with sepsis. Although the results of this study appeared, at least in some aspects, to duplicate the results of the earlier polyclonal antibody studies, sufficient methodological questions were raised concerning both the antigenic specificity of the therapeutic monoclonal antibody and its therapeutic efficacy that its acceptance by the overall medical and scientific community was continuously challenged. While later in vitro studies, some of which were carried out by the writer of this memoriam, unequivocally established the ability of that antibody investigated by Elizabeth and her colleagues to bind to lipid A, the ultimate evidence of therapeutic efficacy was never unequivocally confirmed in septic patients. Parenthetically, similar states befell other experimental strategies to generate protective immunity with anti-lipid A antibodies, as well as related strategies involving the specific targeting of inflammatory mediators generated by immune mediators cells in response to endotoxin LPS. While these multiple defeats placed a collective damper upon many investigators, including Elizabeth Ziegler, in further pursuing the concept of immunological intervention in the treatment of sepsis, they nevertheless established forever, to both the medical community and the general public, the critical importance of sepsis and shock as human diseases that should not be overlooked in efforts of medical researchers to improve human health.
These discouraging investigative findings, coupled with Elizabeth's continuing challenges with diabetes, and the teaching and clinical demands of her medical school, collectively served to limit her future contributions to endotoxin research, but did not diminish her dedication to medicine. Elizabeth was exceptionally talented as a teacher and was continuously recognized as a tireless educator at UCSD, and in 2002 was honored as one of the very first recipients of the UCSD Health Sciences Faculty Award of Excellence in recognition of her contribution to teaching. In addition to this distinguished acknowledgment of her many teaching talents, Elizabeth also received the Paul A. Siple Award for Achievement in Army Research, and the Michigan Infectious Disease Society Distinguished Service Award. She served as a permanent member of the NIH Bacteriology and Mycology 1 Study Section and was a member of the American Society for Clinical Investigation and one of the Founding Members of the International Endotoxin Society.
In addition to her interest in science and medicine, Elizabeth was also a great lover of classical music, and had a special fondness for baroque music. She had great compassion for people of all ages and was as committed to her patients in their 80s and 90s as she was to the 2-and 3-year-old toddlers she faithfully taught the great musical hymns of the Christian Religion in her Church Sunday School class. This passion for life and deep caring for people is accurately reflected by the words of David Bailey, Deputy Vice Chancellor for Health Sciences at UCSD, who noted: 'Elizabeth Ziegler was truly one of a kind, excelling at the bedside, in the laboratory and in the classroom. However, it was her compassion for patients, students and colleagues that I will most fondly remember.' All of us who knew Elizabeth Ziegler would agree 100 percent that this, indeed, describes this wonderful and talented woman. Elizabeth died at The Springs Rehabilitation Facility of Pacific Regions on January 2, 2006. The medical community, and in particular, the endotoxin and infectious disease community, will indeed miss her greatly.
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